ERBB2 and breast cancer: TOP2A gene is coamplified with HER2 gene in approximately 35% of HER2-amplified breast cancers, and TOP2A coamplification, not HER2 amplification, is the predictive marker of an incremental response to anthracycline-based chemotherapy in HER2-amplified breast cancers [7, 20–23].